BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax (Deprecated 2013-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax (Deprecated 2013-01-31) of -$34.00 million for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeBeforeTax · last filed 2013-07-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2013-06-30 was -$34.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was -$10.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2012-06-30 was -$13.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2012-03-31 was -$8.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for fiscal 2012 was -$56.00M, a 207.69% decline from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for fiscal 2011 was $52.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment on derivatives included in net income, before tax (deprecated 2013-01-31) for fiscal 2010 was -$10.00M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax (Deprecated 2013-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|---|
| 2013-06-30 | -$34.00M 10-Q · filed 2013-07-25 | -$44.00M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | -$10.00M 10-Q · filed 2013-04-25 | ||
| 2012-12-31 | -$56.00M 10-K · filed 2013-02-15 | ||
| 2012-06-30 | -$13.00M 10-Q · filed 2013-07-25 | -$21.00M 10-Q · filed 2013-07-25 | |
| 2012-03-31 | -$8.00M 10-Q · filed 2013-04-25 | ||
| 2011-12-31 | $52.00M 10-K · filed 2013-02-15 | ||
| 2010-12-31 | -$10.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |